ISTH 2015 - Sam Schulman, ISTH 2015 Congress President, Professor of Medicine, Thrombosis Service, McMaster University - This cohort study evaluates the safety of perioperative management of dabigatran using a specified protocol. Patients treated with dabigatran and planned for an invasive procedure were eligible for inclusion. The timing of the last dose of dabigatran before the procedure was based on the creatinine clearance and procedure-related bleeding risk. Resumption of dabigatran was pre-specified according to the complexity of the surgery and consequences of a bleeding complication.

свернуть